Unknown

Dataset Information

0

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience.


ABSTRACT: Background:In this study, we retrospectively evaluated a series of metastatic nasopharyngeal carcinoma (mNPC) patients who received oral maintenance chemotherapy using S-1/capecitabine after systemic chemotherapy and local radiation therapy, and aimed to explore potential efficient treatment strategies for this subset of patients. Patients and Methods:Thirty-seven patients with mNPC (19 newly diagnosed metastatic patients and 18 metastatic cases after definitive chemoradiotherapy) who received the treatment strategies mentioned above were analyzed. Results:After a median follow-up time of 37 months, the 3-year progression-free survival and overall survival (OS) rates were 47.6% and 87.7%, respectively. The median time to progression was 27.6 months, while the median OS was not reached at time of last follow-up. The most common acute adverse events were hematological and gastrointestinal toxicity, and all were tolerable and curable. Conclusion:Oral maintenance chemotherapy using S-1/capecitabine in mNPC patients after systemic chemotherapy could yield a superb outcome. Further multicenter prospective clinical trials are warranted.

SUBMITTER: Guo Q 

PROVIDER: S-EPMC7049279 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience.

Guo Qiaojuan Q   Chen Mengwei M   Xu Hanchuan H   Lu Tianzhu T   Zhou Han H   Chen Yanyan Y   Zong Jingfeng J   Xu Yun Y   Chen Bijuan B   Wang Bingyi B   Zhu Lili L   Pan Jianji J   Lin Shaojun S  

Cancer management and research 20200225


<h4>Background</h4>In this study, we retrospectively evaluated a series of metastatic nasopharyngeal carcinoma (mNPC) patients who received oral maintenance chemotherapy using S-1/capecitabine after systemic chemotherapy and local radiation therapy, and aimed to explore potential efficient treatment strategies for this subset of patients.<h4>Patients and methods</h4>Thirty-seven patients with mNPC (19 newly diagnosed metastatic patients and 18 metastatic cases after definitive chemoradiotherapy)  ...[more]

Similar Datasets

| S-EPMC7163084 | biostudies-literature
| S-EPMC7163789 | biostudies-literature
| S-EPMC7672732 | biostudies-literature
| S-EPMC5729473 | biostudies-literature
| S-EPMC2410054 | biostudies-other
| S-EPMC5403079 | biostudies-literature
| S-EPMC6806566 | biostudies-literature
| S-EPMC8855317 | biostudies-literature
| S-EPMC7059341 | biostudies-literature
| S-EPMC2677488 | biostudies-literature